Verrica Pharmaceuticals Inc.
NASDAQ:VRCABiotechnology
-$0.02 today
- Market cap
- $53.94M
- Beta
- 1.49
- P/E (TTM)
- -3.5
- EPS (TTM)
- -$1.67
Volume 0.10M
Average 0.08M
VRCA Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Verrica Pharmaceuticals Inc.NASDAQ: VRCA
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 30.4% from a year ago
Cash & equivalents stood at $20.6M at the end of Q1 FY2026, down 30.4% from a year earlier and down 31.7% from the prior quarter. Over 3 fiscal years it compounded at -4.2% a year.
Context
- Cash & equivalents amounted to 53.1% of total assets at the end of Q1 FY2026, down 17.1 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -30.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 30.15M USD
- Year-over-year change
- -34.9%
- 4-year CAGR
- +17.6%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.15M | -34.9% |
| FY2024 | 2024-12-31 | 46.33M | -33.4% |
| FY2023 | 2023-12-31 | 69.55M | +102.9% |
| FY2022 | 2022-12-31 | 34.27M | +117.6% |
| FY2021 | 2021-12-31 | 15.75M | — |
Cash & Equivalents vs competitors
How VRCA compares with its peers on the latest reported figures
- VRCA's Mar 2026 cash & equivalents of $20.6M is the 3rd highest of the 5 companies compared; the peer median is $34.12M.
- Its year-over-year change of -30.4% is the lowest of 5, against a peer median of +69.8%.
- Cash & equivalents amounts to 53.1% of total assets for VRCA, versus a peer median of 36.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $53.49M | +167.6% | -9.9% | 61.1% | |
| Mar 2026 | $50.75M | -22.5% | +3.2% | 79.7% | |
| Mar 2026 | $20.6M | -30.4% | -4.2% | 53.1% | |
| Mar 2026 | $17.48M | +15.7% | +17.7% | 12.4% | |
| Jun 2026 | $8.27M | +123.9% | -11.3% | 3.5% | |
| Peer median (excluding VRCA) | $34.12M | +69.8% | -3.3% | 36.8% | |
Competitors are the stored peer set for VRCA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 15.75M | 34.27M | 69.55M | 46.33M | 30.15M |
| Short-term Investments | 54.6M | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 487K | 4.42M | 77K | 5.4M |
| Inventory | 0 | 0 | 1.02M | 2.46M | 2.24M |
| Other Current Assets | 0 | 4.36M | 2.55M | 2.31M | 4.76M |
| Total Current Assets | 74.33M | 39.12M | 77.53M | 51.18M | 42.54M |
| Property, Plant & Equipment (Net) | 5.5M | 5.33M | 3.62M | 2.58M | 1.86M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 295K | 276K | 452K | 376K | 2.73M |
| Total Non-current Assets | 5.8M | 5.61M | 4.07M | 2.96M | 4.59M |
| Total Assets | 80.13M | 44.72M | 81.6M | 54.13M | 47.13M |
| Account Payables | 845K | 507K | 2.46M | 1.9M | 2.07M |
| Short-term Debt | 41.69M | 0 | 0 | 12.94M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 782K |
| Other Current Liabilities | 1.67M | 1.4M | 9.04M | 11.59M | 10.44M |
| Total Current Liabilities | 46.06M | 3.46M | 17.02M | 29.01M | 16.44M |
| Long-term Debt | 0 | 0 | 42.87M | 30.98M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 2.65M | 5.07M |
| Total Non-current Liabilities | 1.47M | 1.23M | 44.81M | 34.98M | 5.95M |
| Total Liabilities | 47.52M | 4.69M | 61.83M | 63.99M | 22.39M |
| Common Stock | 3K | 4K | 4K | 9K | 2K |
| Retained Earnings | (138.97M) | (163.45M) | (230.45M) | (307.03M) | (324.91M) |
| Accumulated OCI | (29K) | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 32.61M | 40.03M | 19.76M | (9.86M) | 24.74M |
| Total Debt | 43.41M | 1.53M | 45.51M | 45.94M | 1.63M |
| Net Debt | 27.66M | (32.75M) | (24.04M) | (390K) | (28.52M) |
Verrica Pharmaceuticals Inc.
NASDAQ:VRCA
Intrinsic Alpha fair value
Locked
Current Price
$3.14
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.